1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Material Name: Pegvisomant for Injection

Trade Name: Somavert®
Synonyms: Human Growth Hormone; HG; B2036-PEG; Pegvisomantum
Chemical Family: Mixture
Intended Use: Pharmaceutical product for the treatment of growth hormone overproduction (acromegaly).

2. HAZARDS IDENTIFICATION

Appearance: White sterile lyophilized powder plus sterile diluent.
Signal Word: WARNING

Statement of Hazard: Suspected of damaging the unborn child.

Additional Hazard Information:
- Long Term: Animal studies indicate that this material may cause adverse effects on the developing fetus.
- Known Clinical Effects: Adverse effects most commonly reported in clinical use include gastrointestinal disturbances, changes in liver function, flu-like syndrome, fatigue, nausea, diarrhea and flatulence. Individuals sensitive to this material or other materials in its chemical class may develop allergic reactions. Drugs of this class may cause formation of antibodies, changes in blood sugar.

EU Indication of danger: Toxic to Reproduction: Category 3

EU Hazard Symbols: Xn

EU Risk Phrases: R63 - Possible risk of harm to the unborn child.


Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.
2. HAZARDS IDENTIFICATION

3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pegvisomant</td>
<td>218620-50-9</td>
<td>Not listed</td>
<td>Repr.Cat.3,R63</td>
<td>35-52</td>
</tr>
<tr>
<td>Sodium Phosphate Monobasic, Monohydrate</td>
<td>10049-21-5</td>
<td>Not listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Sodium phosphate, dibasic</td>
<td>7558-79-4</td>
<td>231-448-7</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Mannitol</td>
<td>69-65-8</td>
<td>200-711-8</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Glycine</td>
<td>56-40-6</td>
<td>200-272-2</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

For the full text of the R phrases mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.
Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Measures for Environmental Protections: Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling: Minimize dust generation and accumulation. Avoid breathing dust. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Pegvisomant  
Pfizer OEL TWA-8 Hr: 60µg/m³

Glycine  
Latvia OEL - TWA Listed

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Environmental Exposure Controls: Refer to specific Member State legislation for requirements under Community environmental legislation.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

   Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.
   Eyes: Wear safety glasses or goggles if eye contact is possible.
   Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.
   Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Lyophilized powder plus sterile diluent  
Molecular Formula: Mixture  
Color: White  
Molecular Weight: Mixture
10. STABILITY AND REACTIVITY

Stability: Stable under normal conditions of use.
Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers.

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the active ingredient.

Acute Toxicity: (Species, Route, End Point, Dose)

Pegvisomant
Mouse Subcutaneous Discriminating Dose 10 mg/kg
Mouse Intravenous Discriminating Dose 10 mg/kg
Non-human Primate Intravenous Discriminating Dose 100 mg/kg

Irritation / Sensitization: (Study Type, Species, Severity)

Pegvisomant
Skin Irritation Rabbit Non-irritating
Antigenicity- Passive cutaneous anaphylaxis Mouse Mild
Antigenicity- Passive cutaneous anaphylaxis Monkey Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Pegvisomant
14 Day(s) Mouse Intravenous 3 mg/kg/day NOAEL Liver
14 Day(s) Mouse Subcutaneous 3 mg/kg/day LOAEL Blood Liver
28 Day(s) Monkey Subcutaneous 3 mg/kg/day NOAEL No effects at maximum dose
6 Month(s) Rat Subcutaneous 10 mg/kg/day NOAEL Blood Liver Kidney
6 Month(s) Monkey Subcutaneous 0.3 mg/kg/week NOAEL Bone Marrow

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Pegvisomant
Embryo / Fetal Development Rabbit Subcutaneous 10 mg/kg/day NOAEL Negative
Fertility and Embryonic Development Rabbit Subcutaneous 3 mg/kg/day NOAEL Fetotoxicity
Embryo / Fetal Development Rabbit Subcutaneous 10 mg/kg/day NOAEL Not Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Pegvisomant
Bacterial Mutagenicity (Ames) Salmonella, E. coli Negative
In Vitro Chromosome Aberration Human Lymphocytes Negative

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be avoided.
13. DISPOSAL CONSIDERATIONS

Disposal Procedures: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Symbol: Xn
EU Indication of danger: Toxic to Reproduction: Category 3
EU Risk Phrases: R63 - Possible risk of harm to the unborn child.
EU Safety Phrases: S36/37 - Wear suitable protective clothing and gloves.

OSHA Label:
WARNING
Suspected of damaging the unborn child.

Canada - WHMIS: Classifications
WHMIS hazard class:
Class D, Division 2, Subdivision A

Pegvisomant
Standard for the Uniform Scheduling for Drugs and Poisons: Schedule 4

Sodium Phosphate Monobasic, Monohydrate
Australia (AICS): Listed
15. REGULATORY INFORMATION

Sodium phosphate, dibasic
- CERCLA/SARA Hazardous Substances: 2270 kg final RQ
- Inventory - United States TSCA - Sect. 8(b): Listed
- Australia (AICS): Listed
- EU EINECS/ELINCS List: 231-448-7

Mannitol
- Inventory - United States TSCA - Sect. 8(b): Listed
- Australia (AICS): Listed
- REACH - Annex IV - Exemptions from the obligations of Register: Present
- EU EINECS/ELINCS List: 200-711-8

Glycine
- Inventory - United States TSCA - Sect. 8(b): Listed
- Australia (AICS): Listed
- EU EINECS/ELINCS List: 200-272-2

16. OTHER INFORMATION

Text of R phrases mentioned in Section 3
R63 - Possible risk of harm to the unborn child.

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information. Safety data sheets for individual ingredients.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 4 - First Aid Measures. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 10 - Stability and Reactivity. Updated Section 13 - Disposal Considerations.

Prepared by: Toxicology and Hazard Communication
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet